Skip to search formSkip to main contentSkip to account menu

upamostat

National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

PiperazinesSulfonamides

Narrower (1)

WX-671

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
DCE-MRI biomarkers for monitoring an anti-angiogenic triple combination therapy in experimental hypopharynx carcinoma xenografts with immunohistochemical validation
Background Novel anti-angiogenic treatments are increasingly complementing established cancer therapy strategies in head and neck… 
2013
2013
Activation of the anti-cancer agent upamostat by the mARC enzyme system
Abstract 1. Upamostat (Mesupron®) is a new small molecule serine protease inhibitor. The drug candidate was developed to inhibit… 
2012
2012
Abstract P5-20-01: A randomized double-blind phase II study of the combination of oral WX-671 plus capecitabine vs. capecitabine monotherapy in first-line HER2− negative metastatic breast cancer (MBC…
Background: uPA and its inhibitor PAI-1 play a key role in tumor invasion, metastasis and tumor growth. High levels of uPA and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)